A subsidiary of Open Orphan has started testing a drug that could potentially treat Covid-19.
Open Orphan is a Europe- focused pharma services company specialising in rare disease and so-called orphan drugs.
The tests are being carried out by its London-based subsidiary Hvivo on behalf of its client Nearmedic International.
The drug being tested has both potential anti-viral and anti-inflammatory activity, and therefore could reduce both virus infectivity and disease severity respectively, a statement from Open Orphan said.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).